The determination of von Willebrand factor activity by collagen binding assay

Haemophilia

Volumn 4, Issue SUPPL. 3, 1998, Pages 15-24

  Siekmann, J ^a   Turecek, P L ^a   Schwarz, H P ^a,b  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Collagen binding assay; Diagnostic techniques and procedures; Factor VIII concentrates; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BUFFER; COLLAGEN; COLLAGEN TYPE 3; PEPSIN A; PHOSPHATE; POLYCLONAL ANTIBODY; RISTOCETIN; VON WILLEBRAND FACTOR;

ASSAY; BINDING AFFINITY; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; PHOTOMETRY; PLACENTA; POLYMERIZATION; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

BIOLOGICAL ASSAY; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND FACTOR;

EID: 0031773566     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.0040s3015.x     Document Type: Conference Paper

References (35)

1. Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost 1992; 67: 594-9.
2. Girma JP, Ribba AS, Meyer D. Structure-function relationship of the A1 domain of von Willebrand factor. Thromb Haemost 1995; 74: 156-60.
3. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52: 2708-16.
4. Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thrombos Diathes Haemorrh 1975; 34: 306-8.
5. Ewenstein BM. Von Willebrand's disease. Annu Rev Med 1997; 48: 525-42.
6. Mannucci PM. Biochemical characteristics of therapeutic plasma concentrates used in the treatment of von Willebrand disease. Haemostasis 1994; 24: 285-8.
7. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
8. Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a single collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagulat Fibrinol 1991; 2: 285-91.
9. Siekmann J, Turecek PL, Schwarz HP. Design of a collagen binding assay for determination of the functional activity of von Willebrand factor. Ann Hematol 1997; 74 (Suppl. II): A106.
10. Siekmann J, Turecek PL, Schwarz HP. Die funktionelle Charakterisierung von plasmatischem und rekombinantem von Willebrand Faktor durch Bindung an Collagen. In: Scharrer I, Schramm W (eds) 28. Hämophilie-Symposion 1997, Hamburg. Springer Verlag Berlin, 1999; in press.
11. Karlsson R, Michaelsson A, Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Meth 1991; 45: 229-40.
12. Evans RJ, Austen DEG. Assay of Ristocetin Co-factor using fixed platelets and a platelet counting technique. Br J Haematol 1977; 37: 289-94.
13. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-3.
14. Aihara M, Sawada Y, Ueno K et al. Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-biotin peroxidase complex. Thromb Haemost 1986; 55: 263-7.
15. Fischer B, Mitterer A, Schlokat U, Denbouwmeester R, Dorner F. Structural analysis of recombinant von Willebrand factor. Identification of hetero- and homo-dimers. FEBS Lett 1994; 351: 345-8.
16. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
17. Turecek PL, Furlan M, Lämmle B et al. Cleavage of recombinant von Willebrand factor (vWF) by a vWF-depolymerizing protease. Blood 1996; 88 (Suppl. 1): 326a.
18. Karlsson R, Fält A. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J Immunol Meth 1997; 200: 121-33.
19. Pareti F, Fujimura Y, Dent J, Holland LZ, Zimmermann TS, Ruggeri ZM. Isolation and characterization of a collagen binding domain in human von Willebrand factor. J Biol Chem 1986; 261: 15310-5.
20. Fitzsimmons CM, Cockburn CG, Hornsey V, Prowse CV, Barnes MJ. The interaction of von Willebrand factor (vWF) with collagen: Investigation of vWF-binding sites in the collagen molecule. Thromb Haemost 1988; 59: 186-92.
21. Cockburn CG, Fitzsimmons CM, Barnes MJ. The interaction of fibronectin (fn) with native, polymeric collagen (collagen fibres): Comparison with von Willebrand factor (vWf)-binding by collagen. Thromb Haemost 1989; 61: 378-85.
22. Miller EJ, Gay S. Collagen: An overview. Meth Enzymol 1982; 82: 3-32.
23. Thomas KB, Sutor AH, Altinkaya N, Grohmann A, Zehenter A, Leititis JU. von Willebrand factor-collagen binding activity is increased in newborns and infants. Acta Paediat 1995; 84: 697-9.
24. Thomas KB, Sutor AH, Zieger B et al. A simple test for the determination of the von Willebrand factor function: the collagen binding activity. Hämostaseologie 1994; 14: 133-9.
25. Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites within human von Willebrand factor for monomeric type III collagen. Biochemistry 1986; 25: 8357-61.
26. Kuo HJ, Keene DR, Glanville RW. The macromolecular structure of type-VI collagen - Formation and stability of filaments. Eur J Biochem 1995; 232: 364-72.
27. Linnau Y, Weber A. Manufacture of a high purity FVIII.c/von Willebrand factor complex (Immunate™). Ann Haematol 1993; 66 (Suppl. I): A46.
28. Sadler JE, Matsushita T, Dong ZY, Tuley EA, Westfield LA. Molecular mechanism and classification of von Willebrand disease. Thromb Haemost 1995; 74: 161-6.
29. Auerswald G, Anders O, Budde U et al. Clinical study of the biological efficiency of a high-purity FVIII. C-vWF complex concentrate in patients with von Willebrand disease. Thromb Haemost 1995; 73: 1171.
30. Rodheghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992; 62: 193-9.
31. Menache D, Aronson DL. New treatments of von Willebrand disease: Plasma derived von Willebrand factor concentrates. Thromb Haemost 1997; 78: 566-70.
32. Schwarz HP, Turecek PL, Pichler L et al. Recombinant von Willebrand factor. Thromb Haemost 1997; 78: 571-6.
33. Brinkhous KM, Read MS. Fixation platelets and platelet agglutination/aggregation tests. Meth Enzymol 1989; 169: 149-63.
34. Chang P, Aronson DL. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost 1997; 78: 930-3.
35. Human coagulation factor VIII, Freeze-Dried, Monography 1998:0275. European Phamacopoeia, 3rd edn Suppl. 1998; 336-37.